Comparative Pharmacology
Head-to-head clinical analysis: ADVIL PM versus PIROXICAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL PM versus PIROXICAM.
ADVIL PM vs PIROXICAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. Diphenhydramine is a first-generation antihistamine that antagonizes histamine H1 receptors, causing sedation.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Two caplets (ibuprofen 200 mg, diphenhydramine citrate 38 mg) orally at bedtime as needed for insomnia. Maximum: 2 caplets in 24 hours.
10-20 mg orally once daily; maximum 20 mg/day.
None Documented
None Documented
Ibuprofen: 2-4 hours (terminal); clinical context: steady state achieved in 1 day, not affected by renal impairment. Diphenhydramine: 4-8 hours (terminal); clinical context: prolonged in hepatic impairment.
Clinical Note
moderatePiroxicam + Gatifloxacin
"Piroxicam may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderatePiroxicam + Rosoxacin
"Piroxicam may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderatePiroxicam + Levofloxacin
"Piroxicam may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderatePiroxicam + Trovafloxacin
"Piroxicam may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is 50 hours (range 30-86 hours), allowing once-daily dosing. Prolonged in elderly (up to 80 hours) and in hepatic impairment.
Ibuprofen: Renal (90% as metabolites and conjugates, <10% unchanged); Diphenhydramine: Renal (primarily as metabolites, ~1% unchanged). Fecal excretion is negligible for both.
Approximately 60-70% renal (glomerular filtration and tubular secretion) as unchanged drug and metabolites; 30-40% fecal via biliary excretion. Less than 5% as unchanged drug in urine.
Category C
Category D/X
NSAID/Sedative Combination
NSAID